Stock CAH CARDINAL HEALTH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cardinal Health, Inc.

Equities

CAH

US14149Y1082

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 21:00:02 26/04/2024 BST 		5-day change 1st Jan Change
103.2 USD -0.58% Intraday chart for Cardinal Health, Inc. -4.60% +2.39%
04-25 US FDA sends warning to Cardinal Health for marketing unapproved devices RE
04-24 Evercore ISI Adjusts Cardinal Health's Price Target to $110 From $118, Keeps In Line Rating MT

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 14,039 15,239 16,565 14,240 24,078 25,104 - -
Enterprise Value (EV) 1 19,539 19,243 19,394 14,838 24,736 24,668 23,761 23,438
P/E ratio 10.4 x -4.14 x 27.4 x -15.6 x 94.6 x 18 x 15.4 x 14 x
Yield 4.06% 3.7% 3.41% 3.75% 2.1% 1.96% 2% 2.06%
Capitalization / Revenue 0.1 x 0.1 x 0.1 x 0.08 x 0.12 x 0.11 x 0.11 x 0.1 x
EV / Revenue 0.13 x 0.13 x 0.12 x 0.08 x 0.12 x 0.11 x 0.1 x 0.09 x
EV / EBITDA 7.15 x 6.94 x 7.5 x 6.29 x 10 x 8.67 x 7.61 x 7.03 x
EV / FCF 8.16 x 12.1 x 9.56 x 5.43 x 10.5 x 11.6 x 11.8 x 10.8 x
FCF Yield 12.3% 8.24% 10.5% 18.4% 9.53% 8.63% 8.47% 9.23%
Price to Book 1.63 x 8.55 x 9.29 x -20.6 x -8.32 x -8.33 x -10.4 x -29.6 x
Nbr of stocks (in thousands) 298,060 291,986 290,148 272,427 254,600 243,233 - -
Reference price 2 47.10 52.19 57.09 52.27 94.57 103.2 103.2 103.2
Announcement Date 08/08/19 06/08/20 05/08/21 11/08/22 15/08/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 145,534 152,922 162,467 181,364 205,012 225,164 238,097 254,928
EBITDA 1 2,732 2,773 2,587 2,358 2,464 2,845 3,124 3,334
EBIT 1 2,353 2,384 2,255 1,990 2,057 2,386 2,599 2,768
Operating Margin 1.62% 1.56% 1.39% 1.1% 1% 1.06% 1.09% 1.09%
Earnings before Tax (EBT) 1 1,751 -3,772 323 -769 638 1,536 2,115 2,290
Net income 1 1,363 -3,696 611 -933 261 1,210 1,545 1,689
Net margin 0.94% -2.42% 0.38% -0.51% 0.13% 0.54% 0.65% 0.66%
EPS 2 4.530 -12.61 2.080 -3.350 1.000 5.723 6.696 7.362
Free Cash Flow 1 2,394 1,585 2,029 2,735 2,358 2,128 2,012 2,163
FCF margin 1.64% 1.04% 1.25% 1.51% 1.15% 0.95% 0.85% 0.85%
FCF Conversion (EBITDA) 87.63% 57.16% 78.43% 115.99% 95.7% 74.81% 64.42% 64.88%
FCF Conversion (Net income) 175.64% - 332.08% - 903.45% 175.86% 130.27% 128.06%
Dividend per Share 2 1.910 1.929 1.948 1.960 1.988 2.025 2.061 2.125
Announcement Date 08/08/19 06/08/20 05/08/21 11/08/22 15/08/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3
Net sales 1 43,968 45,457 44,836 47,103 49,603 51,469 50,487 53,453 54,763 57,445 56,103 57,754 58,050 60,685 59,036
EBITDA 1 616 552 647 542 523 566 707 667 679 674 765.5 732.4 719.3 752.1 844.9
EBIT 1 527 467 545 450 423 467 606 560 571 562 651.7 620.6 606.1 636.2 716.9
Operating Margin 1.2% 1.03% 1.22% 0.96% 0.85% 0.91% 1.2% 1.05% 1.04% 0.98% 1.16% 1.07% 1.04% 1.05% 1.21%
Earnings before Tax (EBT) 1 369 -973 -137 -28 110 -137 544 121 -26 490 600.2 482 604.9 647.3 762.6
Net income 1 271 49 -1,391 138 110 -130 345 -64 5 353 477.9 369.5 395 415 472.2
Net margin 0.62% 0.11% -3.1% 0.29% 0.22% -0.25% 0.68% -0.12% 0.01% 0.61% 0.85% 0.64% 0.68% 0.68% 0.8%
EPS 2 0.9400 0.1700 -5.050 0.5000 0.4000 -0.5000 1.340 -0.2500 0.0200 1.430 1.930 1.582 1.620 1.698 1.928
Dividend per Share 2 0.4908 0.4908 0.4908 0.4908 0.4957 0.4957 0.4957 0.5006 0.5006 0.5006 0.5051 0.5069 0.5238 0.5257 0.5276
Announcement Date 09/11/21 03/02/22 05/05/22 11/08/22 04/11/22 02/02/23 04/05/23 15/08/23 03/11/23 01/02/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 5,500 4,004 2,829 598 658 - - -
Net Cash position 1 - - - - - 436 1,343 1,666
Leverage (Debt/EBITDA) 2.013 x 1.444 x 1.094 x 0.2536 x 0.267 x - - -
Free Cash Flow 1 2,394 1,585 2,029 2,735 2,358 2,128 2,012 2,163
ROE (net income / shareholders' equity) 25.7% 39.5% 91.3% 261% - - - -
ROA (Net income/ Total Assets) 3.93% 3.93% 3.84% 3.21% 3.48% 3.7% 4.1% 4.15%
Assets 1 34,703 -94,103 15,904 -29,039 7,500 32,737 37,689 40,743
Book Value Per Share 2 28.90 6.110 6.140 -2.540 -11.40 -12.40 -9.900 -3.490
Cash Flow per Share 2 9.040 6.690 8.260 11.20 10.80 9.400 11.10 11.80
Capex 1 328 375 400 387 481 502 513 526
Capex / Sales 0.23% 0.25% 0.25% 0.21% 0.23% 0.22% 0.22% 0.21%
Announcement Date 08/08/19 06/08/20 05/08/21 11/08/22 15/08/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Cardinal Health, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
103.2 USD
Average target price
112.4 USD
Spread / Average Target
+8.93%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
+2.39% 25.1B
MCKESSON CORPORATION Stock McKesson Corporation
+17.35% 71.39B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+5.38% 8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+6.69% 8.19B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.96% 7.91B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+0.49% 4.54B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.12% 4.31B
EBOS GROUP LIMITED Stock EBOS Group Limited
-3.38% 3.93B
GALENICA AG Stock Galenica AG
-2.61% 3.86B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+22.08% 3.64B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. CAH Stock
  4. Financials Cardinal Health, Inc.